Clinical Trial Update: HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 [Phase 2]

View source ↗

Summary

Phase 2 imaging study aimed to identify HER2-positive metastatic breast cancer patients unlikely to benefit from T-DM1 (ado-trastuzumab emtansine) has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)

Snippet

Sponsor: Jules Bordet Institute | Conditions: HER-2 Positive Breast Cancer | Phase 2 | Status: COMPLETED